MARKET

CASI

CASI

CASI Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.890
-0.010
-0.53%
Closed 17:59 08/07 EDT
OPEN
1.920
PREV CLOSE
1.900
HIGH
1.940
LOW
1.880
VOLUME
679.80K
TURNOVER
--
52 WEEK HIGH
3.820
52 WEEK LOW
1.150
MARKET CAP
228.53M
P/E (TTM)
-3.9400
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CASI stock price target is 3.500 with a high estimate of 3.500 and a low estimate of 3.500.

EPS

CASI News

More
Week In Review: BeiGene Signs $540 Million Deal For China Rights To 3 HBV Candidates
Seeking Alpha · 07/26 16:07
CASI Pharma +11.9% as CEO buys nearly $7.9M worth
Seeking Alpha · 07/24 21:41
CASI Pharmaceuticals prices equity offering
CASI Pharmaceuticals (CASI -12.3%) prices its public offering of 20M at $1.90/share, for gross proceeds of $38M. Underwriters have an option to purchase up
seekingalpha · 07/22 18:39
CASI Pharma Prices 20M Shares At $1.90/Share
Benzinga · 07/22 13:12
CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 20,000,000 shares of it
PR Newswire · 07/22 13:05
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21)
Benzinga · 07/22 11:24
Casi Pharma readies equity offering
CASI Pharmaceuticals (NASDAQ:CASI) launches a public offering of common stock. Price, volume and terms have yet to be announced. Shares down 11% after hour
seekingalpha · 07/22 01:05
CASI Pharma under pressure on public offering
Seeking Alpha - Article · 07/21 20:17

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About CASI

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
More

Webull offers kinds of CASI Pharmaceuticals Inc stock information, including NASDAQ:CASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CASI stock methods without spending real money on the virtual paper trading platform.